All In Biotech

Drug Trial Radar · NCT00127647

An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)

MK0476 Phase III Double-Blind Comparative Study - Allergic Rhinitis

Last checked: Nov 20, 2026Latest source record: Aug 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,375 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,375

Actual

Start

Nov 2004

Primary completion

Apr 2005

Study completion Apr 2005

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Aug 8, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 15 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to evaluate the efficacy and safety of an investigational drug in adult patients with allergic rhinitis.

Conditions

  • Rhinitis, Allergic, Seasonal

Interventions

  • montelukast sodiumDrug

    montelukast sodium; 5 mg, 10 mg QD 2-weeks.

  • Comparator: pranlukastDrug

    Pranlukast 225 mg BID 2-weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite Nasal Symptom Score

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.